Leukemia Diagnosis Outcomes

The Birthplace of CALGB
The group that was to become known as the Cancer and Leukemia Group B (CALGB) took root in 1953, when Dr. James F. Holland initiated a clinical trial or acute leukemia at the National
Cancer Institute. In 1954, before the trial was complete, Holland left the NCI to work at what was then Roswell Park Memorial Institute, but the trial was to continue at both institutions. A multicenter clinical study was thus born.

CALGB research focuses on six major disease areas: leukemia, lymphoma, breast cancer, lung cancer, gastrointestinal malignancies and genitourinary malignancies. In each area, national experts design multimodality treatment programs to help cure more patients with cancer. The CALGB carefully develops and monitors treatment protocols that are often coupled with studies of cancer biology, quality of life, pharmacology and costeffectiveness measures to ensure that improvements in therapy are placed in the proper clinical perspective in today's healthcare marketplace. The CALGB pays close attention to the rights of cancer patients participating in clinical research studies by working with the Department of Health and Human Services' Office for Human Research Protection. RPCI’s clinical researchers actively participate in CALGB-sponsored clinical studies.